Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)
China
· Delayed Price · Currency is CNY 54.76
+0.34 (0.62%)
Apr 29, 2026, 3:00 PM CST
Hangzhou Alltest Biotech Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 178.25 | 220.07 | 302.47 | 180.58 | 1,185 | 765.69 | Upgrade
|
| Depreciation & Amortization | 42.14 | 42.14 | 32.33 | 39.63 | 58 | 15.59 | Upgrade
|
| Other Amortization | 5.88 | 5.88 | 10.28 | 10.13 | 6.95 | 2.13 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.62 | -0.62 | -1.22 | 0.44 | -0.53 | 0.06 | Upgrade
|
| Asset Writedown & Restructuring Costs | -36.33 | -36.33 | 0.01 | -0.6 | 74.72 | 0.02 | Upgrade
|
| Loss (Gain) From Sale of Investments | -0.34 | -0.34 | -57.09 | -57.25 | -33.49 | -28.28 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | 7.87 | 11.33 | 7.82 | 4.08 | Upgrade
|
| Other Operating Activities | 11.49 | 12.6 | 16.61 | 5.12 | 202.81 | 11.46 | Upgrade
|
| Change in Accounts Receivable | -77.63 | -77.63 | -52.12 | -14.05 | 129.53 | -124.24 | Upgrade
|
| Change in Inventory | -20.55 | -20.55 | 19.26 | 12.4 | -13.2 | -264.05 | Upgrade
|
| Change in Accounts Payable | 42.71 | 42.71 | 28.91 | -199.9 | -221.75 | 537.97 | Upgrade
|
| Change in Other Net Operating Assets | 18.51 | 18.51 | 14.23 | 20.69 | 11.45 | - | Upgrade
|
| Operating Cash Flow | 163.67 | 206.59 | 329.52 | 24.76 | 1,361 | 923.87 | Upgrade
|
| Operating Cash Flow Growth | -45.66% | -37.30% | 1230.66% | -98.18% | 47.28% | 48.36% | Upgrade
|
| Capital Expenditures | -157.83 | -219.1 | -220.65 | -533.49 | -270.24 | -140.12 | Upgrade
|
| Sale of Property, Plant & Equipment | -10.24 | 0.69 | 1.69 | 0.29 | 0.02 | 0.02 | Upgrade
|
| Cash Acquisitions | - | - | - | - | -16.61 | - | Upgrade
|
| Investment in Securities | 1,143 | 345.17 | -267.07 | 363.81 | -1,001 | -398.2 | Upgrade
|
| Other Investing Activities | 19.05 | 18.92 | 6.97 | 28.72 | 24.01 | 6.95 | Upgrade
|
| Investing Cash Flow | 993.76 | 145.67 | -479.06 | -140.67 | -1,264 | -531.35 | Upgrade
|
| Long-Term Debt Repaid | - | - | -5.66 | -16.39 | -115.56 | -12.65 | Upgrade
|
| Net Debt Issued (Repaid) | - | - | -5.66 | -16.39 | -115.56 | -12.65 | Upgrade
|
| Issuance of Common Stock | - | - | 8.57 | 8.74 | - | 1,680 | Upgrade
|
| Repurchase of Common Stock | - | - | -36.93 | -22.64 | -34.44 | - | Upgrade
|
| Common Dividends Paid | -195.11 | -195.11 | -232.66 | -528.7 | -215.62 | -107.81 | Upgrade
|
| Other Financing Activities | -68.76 | 17.1 | -6.05 | 0.2 | 3.7 | -39.37 | Upgrade
|
| Financing Cash Flow | -263.87 | -178.01 | -272.73 | -558.79 | -361.91 | 1,520 | Upgrade
|
| Foreign Exchange Rate Adjustments | -25.99 | -11.84 | 5.98 | 9.48 | 67.86 | -18.72 | Upgrade
|
| Net Cash Flow | 867.57 | 162.43 | -416.29 | -665.22 | -197.36 | 1,894 | Upgrade
|
| Free Cash Flow | 5.84 | -12.5 | 108.87 | -508.73 | 1,090 | 783.75 | Upgrade
|
| Free Cash Flow Growth | -91.32% | - | - | - | 39.13% | 33.84% | Upgrade
|
| Free Cash Flow Margin | 0.65% | -1.38% | 12.56% | -67.41% | 32.18% | 41.84% | Upgrade
|
| Free Cash Flow Per Share | 0.07 | -0.16 | 1.38 | -6.42 | 13.76 | 10.48 | Upgrade
|
| Cash Income Tax Paid | 56.52 | 27.66 | 8.11 | 15.37 | 85.85 | 65.73 | Upgrade
|
| Levered Free Cash Flow | -61.89 | -104.34 | 10.23 | -647.33 | 792.39 | 532.31 | Upgrade
|
| Unlevered Free Cash Flow | -61.89 | -104.34 | 10.49 | -646.42 | 793.75 | 532.72 | Upgrade
|
| Change in Working Capital | -36.82 | -36.82 | 18.26 | -164.61 | -140.52 | 153.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.